Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL ‐13 inhibition
Allergy · 2023-11 · 78 (11) · 2875-2891
DOI: 10.1111/all.15811 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 16.07.2023. Verfasst von Eric L Simpson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: LEO Pharma Inc..
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic, inflammatory, intensely pruritic skin disorder associated with significant patient burden. Interleukin (IL)‐13 is a cytokine that acts as a driver of immune dysregulation, skin‐barrier dysfunction, and microbiome dysbiosis that characterizes AD, and is consistently overexpressed in AD skin. Tralokinumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody that binds specifically to IL‐13 with high affinity, thereby inhibiting subsequent downstream IL‐13 signaling. Three pivotal phase 3 clinical trials demonstrated that tralokinumab 300 mg every other week, as monotherapy or in combination with topical corticosteroids as needed, provides significant improvements in signs and symptoms of moderate‐to‐severe AD, as measured by Investigator's Global Assessment 0/1 (clear/almost clear) and Eczema Area and Severity Index‐75 at Week 16. Improvements were observed soon after tralokinumab initiation and were maintained over 52 weeks of therapy. Tralokinumab significantly improved patient‐reported outcomes such as itch and sleep, and demonstrated a safety profile comparable with placebo; conjunctivitis during tralokinumab therapy was generally mild. Similar results were observed in a phase 3 adolescent trial. The role of IL‐13 in the pathophysiology of AD justifies a targeted approach and a wealth of clinical data supports tralokinumab as a new therapeutic option for people with moderate‐to‐severe AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
- Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Departments of Dermatology and Pediatrics, University of California San Diego and Rady Children's Hospital San Diego, San Diego, California, USA.
- Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colorado, USA.
- Department of Dermatology and Allergy, Christine Kühne-Center for Allergy Research and Education (CK-CARE), University Hospital Bonn, Bonn, Germany.
- LEO Pharma, Madison, New Jersey, USA.
ORCID-Profile: Emma Guttman-Yassky, Thomas Bieber, Jonathan I Silverberg
Förderung
- LEO Pharma Inc.
Zitieren
APA
Simpson, E. L., Guttman-Yassky, E., Eichenfield, L. F., Boguniewicz, M., Bieber, T., Schneider, S., Guana, A., & Silverberg, J. I. (2023). Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL ‐13 inhibition. Allergy, 78(11), 2875-2891. https://doi.org/10.1111/all.15811
Vancouver
Simpson EL, Guttman-Yassky E, Eichenfield LF, Boguniewicz M, Bieber T, Schneider S, et al. Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL ‐13 inhibition. Allergy. 2023;78(11):2875-2891. doi:10.1111/all.15811
BibTeX
@article{Simpson2023,
author = {Simpson, Eric L and Guttman-Yassky, Emma and Eichenfield, Lawrence F and Boguniewicz, Mark and Bieber, Thomas and Schneider, Shannon and Guana, Adriana and Silverberg, Jonathan I},
title = {Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL ‐13 inhibition},
journal = {Allergy},
year = {2023},
volume = {78},
number = {11},
pages = {2875--2891},
doi = {10.1111/all.15811}
}
EUVIMED